Related Experiment Video
Updated: Nov 29, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Two Novel Compounds with Tri-aryl Structures as Effective Anti-Breast Cancer Candidates In-vivo
Ahoo Afsharinasab1,2, Fariborz Moayer3, Mohsen Amini4
1Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran (IAUPS).
Abstract:
Prognosis of metastatic breast cancer is very poor which urges the necessity to develop novel potential drug candidates. We assessed two compounds with tri-aryl structures (A and B) for their potency to reduce primary breast tumor growth and lung metastasis in 4T1 mice model. MTT assay, 4T1 mammary mouse model, and immunohistochemistry experiments were used in this study. In-vitro results exhibited an anti-proliferative effect for compounds A and B towards MDA-MB-231 cancer cells. Our in-vivo results displayed that administered compounds A and B could suppress the size of the primary tumor and the number of lung metastatic foci in 4T1 BALB/c mice model. Histopathological analysis revealed that treatment of both compounds resulted in necrosis. Our findings provide new evidence that compound B may be promising for slowing the growth of tumor along with metastatic foci via COX-2 independent pathway.
Insights
Novel tri-aryl compounds A and B show anti-cancer properties. Compound B effectively slowed primary tumor growth and lung metastasis in a mouse model, potentially via a COX-2 independent pathway.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic breast cancer has a poor prognosis, necessitating new therapeutic strategies.
- Tri-aryl compounds are being explored for their potential anti-cancer activities.
Purpose of the Study:
- To evaluate the efficacy of two tri-aryl compounds (A and B) in inhibiting primary tumor growth and lung metastasis.
- To investigate the anti-proliferative effects of compounds A and B on breast cancer cells.
Main Methods:
- In vitro anti-proliferative assays using MDA-MB-231 cancer cells.
- In vivo studies utilizing the 4T1 mammary mouse model.
- Immunohistochemistry and histopathological analysis for tumor and metastasis assessment.
Main Results:
- Compounds A and B demonstrated in vitro anti-proliferative effects against MDA-MB-231 cells.
- In vivo administration of compounds A and B suppressed primary tumor size and reduced lung metastatic foci in the 4T1 mouse model.
- Histopathological analysis confirmed treatment-induced necrosis in both compound groups.
Conclusions:
- Compound B shows promise as a therapeutic agent for slowing tumor growth and metastasis.
- The anti-metastatic effects of compound B may operate through a COX-2 independent pathway.
